SatisfACtion: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy.

Nature et Objectif:
This Phase I/II open-label, multi-center trial aims to evaluate the safety, tolerability, and anti-tumor activity of [225Ac]Ac-PSMA-R2—a targeted radioligand therapy—in adult men with PSMA-positive metastatic prostate cancer. The study includes patients with both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC), with or without prior treatment using 177Lu-PSMA therapy.